Faculty Profiles

Colleges and Departments

Dr. Liqin Du

  • Associate Professor - Chemistry and Biochemistry

Biography and education

2009: Postdoctoral Fellow, McDermott Center for Human Growth and Development, UT Southwestern Medical Center at Dallas, Dallas, TX.

2004: Nutritional Sciences, University of Kentucky, Lexington, KY.

1998: Master of Medicine, Shanghai Second Medical University, Shanghai, China.

1992: Bachelor of Medicine (MD equivalent), Shanghai Medical University, Shanghai, China.

Teaching Interests

Research Interests

  • Du, Liqin (Principal). Administrative Supplement to existing NIH grant - Equipment replacement, National Institute of Health, NCI, R15, Federal, $222234.96. (Submitted: September 29, 2025, Funded: December 1, 2025 - June 30, 2028). Grant.
  • Du, Liqin (Principal). Discovering targets for neuroblastoma differentiation therapy from the human druggable genome, National Institute of Health, NCI, R15, Federal, $531550. (Submitted: October 25, 2024, Funded: July 4, 2025 - June 30, 2028). Grant.
  • Du, Liqin (Principal). Molecular and therapeutic mechanisms of differentiation-inducing microRNA miR-506-3p in neuroblastoma, National Institute of Health, NCI, R15, Federal, $445639. (Submitted: June 6, 2019, Funded: September 1, 2020 - August 31, 2024). Grant.
  • Du, Liqin (Principal), Percent Contribution: %10, Kornienko, Alexander (Other), Percent Contribution: %5, Houhgton, Peter (Other), Percent Contribution: %1. Discovery of new differentiation agents for neuroblastoma therapy, National Institute of Health, NCI, R15, resubmissiom, Federal, $461574. (Funded: August 1, 2017 - July 31, 2020). Grant.
  • Du, Liqin (Principal). Targeting the human druggable genome for neuroblastoma differentiation therapy, Texas State University, REP Program, Texas State University, $8000. (Submitted: October 9, 2024, Funded: January 27, 2025 - May 31, 2026). Grant.
View all grants
  • Zhao, G., Du, L., Zhang, L., & Jia, Y. (2021). LIM domain only 1: an oncogenic transcription cofactor contributing to the tumorigenesis of multiple cancer types. Chinese Medicine Journal, 134(9), 1017–1030. https://doi.org/10.1097/CM9.0000000000001487
  • Zhao, Z., Shelton, S. D., Oviedo, A., Baker, A. L., Bryant, C. P., Omidvarnia, S., & Du, L. (2020). The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression. Journal of Experimental and Clinical Cancer Research, 39(1), 41. https://doi.org/10.1186/s13046-020-1531-2.
  • Saucedo, A., Muppidi, S., Smith, J. L., Jemal, M., Mesa-Diaz, N. L., Vernaza, A., … Kerwin, S. M. (2025). Caffeic acid phenethyl amide and analogues as anticancer agents against neuroblastoma. Book of Abstracts of the 269th ACS National Meeting & Exposition. Retrieved from https://www.fasebj.org/doi/abs/10.1096/fasebj.2019.33.1_supplement.634.5
  • Cardus, D. F., Smith, M. T., Vernaza, A., Smith, J. L., Del Buono, B., Parajuli, A., … Du, L. (2024). Systematic Analysis of miR-506-3p Target Genes Identified Key Mediators of Its Differentiation-Inducing Function. Genes, 15(10), 1–13. Retrieved from DOI: 10.3390/genes15101268
  • Saucedo, A., Subbarao, M., Jemal, M. J., Mesa-Diaz, N. L., Smith, J. L., Vernaza, A., … Kerwin, S. M. (2024). Flow and On-Water Synthesis and Cancer Cell Cytotoxicity of Caffeic Acid Phenethyl Amide (CAPA) Derivatives. Int J Mol Sci., 25(15), 1–11. https://doi.org/10.3390/genes15101268
View all scholarly/creative works
  • Award / Honor Recipient: Recipient, 2025 CoSE Excellence in Scholarly/Creative Activities Award, Texas State University. October 6, 2025
  • Award / Honor Recipient: Recipient, 2024 Presidential Research Award for Faculty Development Leave (2024 Fall semester), Texas State University. July 2, 2024 - May 31, 2025
  • Award / Honor Nominee: Nominee, 2020 Dreyfus Teacher-Scholar Award, Texas State University. June 2, 2020
  • Award / Honor Nominee: Nominee, 2020 Presidential Award for Excellence in Scholarly/Creative Activities, Texas State University. February 3, 2020
  • Award / Honor Recipient: Hua Rui Prize, Sino-Swed Pharmaceutical Corp. Ltd. 1997
View all awards
  1. Member

    CoSE undergraduate Scholarship Committee

  2. Member

    IMBC admission committee

  3. Member

    Department safety committee

  4. Member

    Department Space Committee

  5. Member

    Department Personnel Committee

  6. Editorial Review Board Member

    Technology in Cancer Research and Treatment (TCRT)

  7. View all activities